Guardant Health/$GH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Guardant Health
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Ticker
$GH
Sector
Primary listing
Industry
Health Care Providers & Services
Headquarters
Employees
2,010
ISIN
US40131M1099
Website
Guardant Health Metrics
BasicAdvanced
$6.2B
-
-$3.38
1.45
-
Price and volume
Market cap
$6.2B
Beta
1.45
52-week high
$52.92
52-week low
$20.14
Average daily volume
2M
Financial strength
Current ratio
4.106
Quick ratio
3.606
Long term debt to equity
-509.08
Total debt to equity
-520.909
Interest coverage (TTM)
-166.70%
Profitability
EBITDA (TTM)
-413.046
Gross margin (TTM)
61.34%
Net profit margin (TTM)
-53.82%
Operating margin (TTM)
-58.73%
Effective tax rate (TTM)
-0.28%
Revenue per employee (TTM)
$390,000
Management effectiveness
Return on assets (TTM)
-18.64%
Return on equity (TTM)
456.48%
Valuation
Price to revenue (TTM)
7.969
Price to book
-24.67
Price to tangible book (TTM)
-23.76
Price to free cash flow (TTM)
-20.231
Free cash flow yield (TTM)
-4.94%
Free cash flow per share (TTM)
-247.29%
Growth
Revenue change (TTM)
28.20%
Earnings per share change (TTM)
-14.41%
3-year revenue growth (CAGR)
25.55%
3-year earnings per share growth (CAGR)
-6.47%
What the Analysts think about Guardant Health
Analyst ratings (Buy, Hold, Sell) for Guardant Health stock.
Bulls say / Bears say
Guardant Health's Shield test received FDA approval as a primary screening option for colorectal cancer and is now commercially available in the U.S., potentially expanding its market reach. (lifesciencereport.com)
Analysts have a consensus 'Buy' rating for Guardant Health, with an average 12-month price target of $52.32, indicating confidence in the company's growth prospects. (marketbeat.com)
The Goldman Sachs Group raised its price target for Guardant Health to $56.00, reflecting optimism about the company's future performance. (marketbeat.com)
Guardant Health has a low Altman Z-score of 0.27, suggesting potential financial distress and raising concerns about its financial stability. (gurufocus.com)
The company faces intense competition in the genomic profiling market, with rivals potentially having greater resources and market penetration, which could impact Guardant Health's market share. (tipranks.com)
Guardant Health has a high debt-to-equity ratio, indicating a riskier financing structure compared to its competitors, which could pose challenges in adverse market conditions. (obermatt.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
Guardant Health Financial Performance
Revenues and expenses
Guardant Health Earnings Performance
Company profitability
Guardant Health News
AllArticlesVideos
Medical Services Name Flirts With A Buy Point
Investors Business Daily·4 days ago
Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening
Business Wire·2 weeks ago
New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Guardant Health stock?
Guardant Health (GH) has a market cap of $6.2B as of June 27, 2025.
What is the P/E ratio for Guardant Health stock?
The price to earnings (P/E) ratio for Guardant Health (GH) stock is 0 as of June 27, 2025.
Does Guardant Health stock pay dividends?
No, Guardant Health (GH) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Guardant Health dividend payment date?
Guardant Health (GH) stock does not pay dividends to its shareholders.
What is the beta indicator for Guardant Health?
Guardant Health (GH) has a beta rating of 1.45. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.